INBX Wutah pendapatan triwulanan Inhibrx Biosciences

Simbol lan logo merek Inhibrx Corp (INBX)

Inhibrx Biosciences adheres to bioethics and environmental standards for waste disposal, focusing on the autonomous development of its own oncology pipeline. The quarterly revenue growth rate confirms the current trend, where the 0.00 level records fresh values. Inhibrx Biosciences creates advanced multivalent antibodies with unique molecular structures for high-precision tumor destruction.

Inhibrx Corp (INBX) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 20.11.2026

Inhibrx Biosciences, Inc. (INBX) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
- data dhuwit lan arus kas:
Analisis umum perusahaan:Inhibrx (INBX)
Barang unggulan inhibrx.com

The operational activities of Inhibrx Biosciences (INBX) are directly reflected in the quarter-over-quarter revenue growth dynamics. This metric captures the percentage change in sales volume between consecutive periods, revealing the pace of business scaling. The current value of 0.00 allows for an assessment of monetization efficiency against the backdrop of a dense oncology R&D pipeline. A decline in this indicator could signal a fundamental slowdown prior to the release of new therapeutic candidates.

Pesaing utama

INCY - Wutah pendapatan kuartal marang kuartal|Owah-owahan pendapatan dibandhingake kuartal kepungkur HUTCHMED (HCM)|NUVB: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Day One Bio DAWN|Wutah dodolan triwulanan MNPR|Tingkat wutah pendapatan sajrone kuartal I-Mab Biopharma IMAB|Wutah dodolan triwulanan FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Tambahing pendapatan triwulanan|Nuvectis Pharma, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal CHRS (Coherus BioSciences)|Corbus Pharma - Wutah pendapatan triwulanan|Tambahing pendapatan triwulanan CRDF (cardiffoncology.com)|BYSI: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal BioAtla Corp (BCAB)|Wutah pendapatan kuartal marang kuartal Lixte Biotechnology Holdings, Inc.|CTXR: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan CLRB|Wutah pendapatan triwulanan BioLineRx Corporation (BLRX)|Wutah pendapatan kuartal marang kuartal Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Dinamika pendapatan kuartal marang kuartal|KZIA: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Silexion Therapeutics|NuCana plc (NCNA) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan Chimerix, Inc|Wutah dodolan triwulanan CYCC|Wutah dodolan triwulanan G1 Therapeutics (GTHX)|Wutah pendapatan kuartal marang kuartal Kronos Bio Corporation (KRON)|Kintara - Wutah dodolan kuartal marang kuartal|Oncternal Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal PRTG (Portage)